BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 5, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2006

View Archived Issues

Istradefylline shows potential in restless legs syndrome

Read More

XP-13512 improves restless legs syndrome symptoms in polysomnography trial

Read More

Transgene and NCI sign melanoma CRADA letter of intent

Read More

Enrollment completed in study of DAC:GRF for HIV-associated lipodystrophy

Read More

Affibody and GE Healthcare enter research agreement

Read More

PharmaGap seeks to outlicense or sell PhG-alpha1

Read More

Positive findings in European study of Repel-CV

Read More

Corgentech changes name to Anesiva

Read More

Enrollment open in phase IIa study of NCX-1000 in portal hypertension

Read More

Phase I study of CR011-vcMMAE for melanoma commences

Read More

Preclinical findings for Mymetics' HIV-AIDS prophylactic vaccine candidate

Read More

Desonate NDA accepted for filing

Read More

Compound Therapeutics changes name to Adnexus Therapeutics

Read More

Bone loss treatment ACE-011 enters phase I

Read More

Clearance for phase I/II trial protocol of AMZ-0026 in HIV patients

Read More

Phase I study cleared to begin for CT-322 in cancer

Read More

DG-041 begins phase II program for peripheral artery disease

Read More

AA-4500 highly effective in treatment of Dupuytren's contracture

Read More

bPiDDB blocks nicotine-induced dopamine release in the nucleus accumbens

Read More

Novel human anticocaine monoclonal antibody limits cocaine distribution to the brain

Read More

FDA approval for extended- and immediate-release oxymorphone hydrochloride

Read More

Accelerated approval for Prezista in HIV combination therapy

Read More

Lumigan approved for first-line use

Read More

Recent patents describe novel therapeutic agents for atopic dermatitis, psoriasis

Read More

Novel treatments for inflammatory disorders claimed in recent patents

Read More

Recent patents disclose new therapeutic agents for psychological disorders

Read More

Fenofibrate/metformin combination effective in patients with metabolic syndrome

Read More

Extract from Artemisia dracunculus shows promising antidiabetic properties

Read More

Favorable pharmacokinetic profile of apricitabine in healthy subjects

Read More

Novel topoisomerase II inhibitor shows potent antitumor activity in vivo

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 4, 2025.
  • Illustration of chromosome unraveling down to the DNA

    First phase of synthetic human genome project successfully completes

    BioWorld
    The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • 3D Euro symbol

    Laigo raises €11.5M seed money for targeted protein degradation

    BioWorld Science
    Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing